Bionano Genomics, Inc. 8-K

What Happened
Bionano Genomics, Inc. announced via an 8-K filed May 28, 2026, that it repaid in full all outstanding Senior Secured Convertible Debentures on the scheduled maturity date of May 26, 2026. In accordance with the debenture terms, any liens on the company’s assets and related covenants were terminated. The company issued a press release about the extinguishment (Exhibit 99.1) and the report was signed by Interim CEO Albert A. Luderer, Ph.D.

Key Details

• Repayment date: May 26, 2026 (scheduled maturity date).
• Instrument retired: Senior Secured Convertible Debentures (the “Debentures”).
• Legal effects: Liens on assets and covenants under the debenture agreements were terminated per their terms.
• Filing/notice: 8-K filed May 28, 2026; press release attached as Exhibit 99.1; signed by Interim CEO Albert A. Luderer.

Why It Matters
Retiring the senior secured convertible debentures removes a class of secured debt and the associated contractual restrictions, which can affect the company’s leverage, liquidity needs, and operational flexibility. Investors should watch subsequent filings (quarterly reports and press releases) for details on how the repayment was funded and any effects on Bionano’s capital structure and cash position.